Navigation Links
FDA grants Genentech's Perjeta® (pertuzumab) accelerated approval for use before surgery in people with HER2-positive early stage breast cancer
Date:10/1/2013

(September 30, 2013) The U.S. Food and Drug Administration (FDA) granted accelerated approval of a Perjeta (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.

This approval is based primarily on data from a Phase II study showing that nearly 40 percent of people receiving the combination of Perjeta, Herceptin (trastuzumab) and docetaxel chemotherapy had no evidence of tumor tissue detectable at the time of surgery (known as a pathological complete response, or pCR). The most common severe (Grade 3 or higher) AEs for the Perjeta regimen were neutropenia (decrease in a certain type of white blood cell, 44.9 percent), febrile neutropenia (fever associated with decrease in a certain type of white blood cell, 8.4 percent), leukopenia (decrease in overall white blood cells, 4.7 percent) and diarrhea (5.6 percent).

This new neoadjuvant indication for Perjeta is for use prior to surgery in combination with Herceptin and docetaxel chemotherapy in people with HER2-positive, locally advanced, inflammatory, or early stage (tumor is greater than two centimeters in diameter or node positive) breast cancer. Perjeta should be used as part of a complete treatment regimen for early stage breast cancer. This use of Perjeta is based on an improvement in the percentage of people who had no evidence of cancer in the breast or lymph nodes at the time of surgery. Currently, no data have shown whether or not treatment with Perjeta prior to surgery improves survival. The safety of Perjeta as part of a doxorubicin (chemotherapy)-containing regimen has not been established. The safety of Perjeta administered for greater than six cycles for early stage breast cancer has not been established. Please see Perjeta full Prescribing Information including Most Serious Side Effects for additional Important Safety Information at http://www.perjeta.com.

Background on Neoadjuvant Treatment:

Upon receiving an early stage breast cancer diagnosis, a person typically undergoes surgery and may then receive a medicine in the "adjuvant" (post-surgery) setting. Neoadjuvant treatment is another treatment option given after diagnosis but before surgery. Neoadjuvant treatment may allow a doctor to quickly access whether a medicine is working, and may also reduce a tumor's size so it is easier to surgically remove.

WHY THIS APPROVAL IS IMPORTANT

  • Treating people with breast cancer early, before the cancer has spread, may offer the best chance of preventing the disease from returning.
  • The Perjeta regimen is the first treatment approved under a new FDA pathway for neoadjuvant use in breast cancer.
  • This new approval pathway makes Perjeta available to people with high-risk, early stage breast cancer more quickly than is possible with traditional approvals.
  • HER2-positive breast cancer is a particularly aggressive form of the disease that affects approximately 25 percent of people with breast cancer.


'/>"/>

Contact: Russell Grant
grantr@fleishman.com
212-453-2430
Fleishman-Hillard
Source:Eurekalert

Related medicine news :

1. Professors at Purchase College and Columbia University Receive More Than $500,000 in Grants to Study New Ways to Reduce Anxiety Disorders
2. Canon and Evergreen Help Thirty Community Groups Across Canada Plant Native Trees with $150,000 in Grants
3. Cashless Nigeria: Central Bank Of Nigeria Grants Globasure Approval to Operate as a Payment Terminal Service Provider (PTSP)
4. American Brain Tumor Association Seeks Inventive Ideas for Research Discovery Grants
5. 2 Georgia cancer patient support organizations to receive Survivor Circle grants from ASTRO
6. Life Sciences Discovery Fund announces $3.7m in research and development grants
7. Mount Sinai Grants Exclusive License to Plexcera Therapeutics to Develop Treatments for Farber Disease and Cystic Fibrosis
8. New NIH grants to investigate disease-related variations in genetic makeup
9. NIH grants Brown University $11M for brain research
10. ASTRO awards $34,500 in individual grants to top researchers presenting at the 2013 Annual Meeting
11. ASTRO to award $675,000 in junior faculty research grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Christie ... today announced an alliance with B. Braun Medical Inc. , a leader in ... in patient care with as many as 90 percent of hospital patients receiving a ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... On the heels of Thinksport’s award-winning sunscreen they’ve used the same scientific approach ... works! , Countless deodorants flood the aisles that contain harmful chemicals that should ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Goodcents Deli ... open in the Lincoln, Neb. area this year. , The first new location ... The second location will open at 84th and Northern Lights Drive this fall. And ...
(Date:4/26/2017)... ... 26, 2017 , ... Jump Technologies, Inc., an innovative software ... completed a round of funding to accelerate its growth strategies. The $3.5 million ... is a growth equity firm focused on investments in healthcare and technology companies. ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... that describes the adoption of e-prescribing as measured in Part D Medicare data. ... deliver prescriptions to pharmacies, either using e-prescribing, faxes or paper. The PaPR ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology: